Ilumya is called Ilumetri in Europe.
Information about Ilumya (Tildrakizumab)
Ilumya (Tildrakizumab) is a monoclonal antibody that selectively inhibits interleukin-23 (IL-23), a key cytokine involved in inflammatory processes. It is primarily used in the treatment of moderate to severe plaque psoriasis.
Product Highlights
- Approved for the treatment of adults with this chronic skin condition.
Key Ingredient
Key Benefits
- Demonstrates significant improvements in skin clearance and quality of life for patients with psoriasis.
- Generally well-tolerated with a manageable safety profile compared to traditional systemic therapies.
- A less frequent dosing schedule improves patient adherence to treatment.
Direction of Use
- Administered as a subcutaneous injection, typically starting with two initial doses, followed by maintenance dosing every 12 weeks.
- Follow proper injection techniques as advised by a healthcare provider.
Safety Concerns
- Common side effects may include injection site reactions, upper respiratory infections, and headache.
- Increased risk of infections and potential for allergic reactions; may require monitoring for tuberculosis and other infections.
- Patients should have regular check-ups to monitor for effectiveness and any adverse effects.
Avoid Ilumya (Tildrakizumab) If
- Known hypersensitivity to Tildrakizumab or any of its components.
- Presence of an active infection or untreated tuberculosis.
- Should be avoided unless the advantages outweigh the potential risks.
This product requires special packaging to maintain its integrity during the shipping process. DO NOT USE THIS MEDICATION if the attached temperature indicator shows that the medication was exposed to temperatures below 2 degrees or above 8 degrees Celsius, and contact the pharmacy immediately.
